Thuja Capital

Portfolio 2009

Company: Fabpulous B.V. - Visit website

Fund: Thuja Capital Healthcare Fund I

Year: 2009

Status: Active

Fabpulous develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability (lateral flow). The first application is a rapid h-FAPB test as an aid in the early diagnosis of a heart infarct.

Company: Cavadis B.V. - Visit website

Fund: Thuja Capital Healthcare Seed Fund I

Year: 2009

Status: Active

Cavadis is a biomarker company aiming to develop in vitro diagnostics for cardiovascular risk assessment.

Browse our portfolio of companies by Fund, Year or Status

• Fund
  • AlpInvest Life Sciences
  • Thuja Capital Healthcare Fund I
  • Thuja Capital Healthcare Fund II
  • Thuja Capital Healthcare Seed Fund I
  • Thuja Capital Healthcare Seed Fund II

• Year
  • Prior to 2008
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018

• Status
  • Active
  • Realized

• News

  • 22 May 2018, Eindhoven – Salvia BioElectronics B.V. announced today that it secured € 1.3 million in seed funding to develop a minimally invasive bioelectronics solution for people suffering from chronic neurological disease. Read further …

  • 8 May, 2018, Utrecht, The Netherlands – Thuja Capital announced it has sold its shareholding in NightBalance B.V. (The Hague, Netherlands) to Royal Philips (NYSE: PHG, AEX: PHIA). Read further …

  • March 29, Wageningen, The Netherlands. NutriLeads, a Dutch Health Ingredients company announces that its NUTRI-NEED project has been selected for €2.5 million funding under the European Innovation Council SME Instrument (phase 2). Read further …

• Events

  • 26 June 2018 – Michel will give a lecture on venture capital at the BioBusiness Summer School

  • 27 June 2018 – Florian Ludwig will give a presentation at the Innovation track of the Device Development Workshop organised by CSI Focus Innovation. More information at www.csi-foundation.org.